基于疼痛轨迹的时点匹配预防性镇痛在胸腔镜肺癌手术患者中的应用

Application of time-point matched preventive analgesia based on pain trajectory in patients undergoing thoracoscopic surgery for lung cancer

目的探讨基于疼痛轨迹的时点匹配预防性镇痛在胸腔镜肺癌手术患者中的应用效果。方法根据住院时间将行胸腔镜肺癌手术患者分为两组,2023年4-6月收治的67例患者作为对照组,实施常规术后镇痛;2023年7-9月收治的68例患者作为试验组,实施基于疼痛轨迹的时点匹配预防性镇痛。比较两组术后疼痛情况、首次下床活动时间、胸腔引流管留置时间、术后住院时间和镇痛满意度。结果试验组术后中重度疼痛发生率为30.88%,对照组为50.75%;对照组中重度疼痛持续时间1(0,2)d,试验组为0(0,1)d,两组比较,差异有统计学意义(均P<0.05)。试验组术后首次下床活动时间、胸腔引流管留置时间显著短于对照组,镇痛满意度评分显著高于对照组(均P<0.05);两组术后住院时间比较,差异无统计学意义(P>0.05)。结论基于疼痛轨迹的时点匹配预防性镇痛干预能实现精准镇痛,降低患者疼痛程度,提升患者舒适度,提高术后镇痛质量。

Objective To investigate the effectiveness of time-point matching preventive analgesia based on pain trajectory in patients undergoing thoracoscopic surgery for lung cancer.Methods A total of 67 patients admitted from April to June 2023 were assigned into the control group,who received routine postoperative analgesia,and another 68 patients admitted from July to September 2023 were assigned into the experimental group,who received time-point matched preventive analgesia based on pain trajectory.After the intervention,the two groups were compared in terms of postoperative pain,time to first mobilization,duration of chest drainage tube indwelling,length of hospitalization,and satisfaction with analgesia.Results The incidence rates of moderate and severe pain in the experimental group were 30.88%versus 50.75%in the control group,respectively,with median pain duration of 1(0,2)d versus 1(0,2)d,respectively.These differences were statistically significant(P<0.05 for both).The experimental group had significantly shorter time to first mobilization,shorter duration of chest drainage tube indwelling,and higher satisfaction with analgesia compared to the control group(P<0.05 for all).There was no statistical difference in postoperative hospitalization days between the two groups(P>0.05).Conclusion Time-point matched preventive analgesic intervention based on pain trajectory can achieve precise analgesia,improve comfort level and the quality of analgesia in patients undergoing thoracoscopic surgery for lung cancer.